



(51) International Patent Classification:

C07K 14/705 (2006.01) C12N 15/62 (2006.01)
C12N 5/0783 (2010.01)

(21) International Application Number:

PCT/US2022/016582

(22) International Filing Date:

16 February 2022 (16.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

63/149,952 16 February 2021 (16.02.2021) US

(71) Applicant: **A2 BIOTHERAPEUTICS, INC.** [US/US];
30301 Agoura Road, Suite 210, Agoura Hills, California
91301 (US).(72) Inventors: **OH, Jylyun**; c/o A2 Biotherapeutics, Inc.,
30301 Agoura Rd, Suite 210, Agoura Hills, California
91301 (US). **XU, Han**; c/o A2 Biotherapeutics, Inc., 30301
Agoura Rd, Suite 210, Agoura Hills, California 91301
(US). **KAMB, Carl Alexander**; c/o A2 Biotherapeutics,Inc., 30301 Agoura Rd, Suite 210, Agoura Hills, California
91301 (US). **ANDO, Yuta**; c/o A2 Biotherapeutics,
Inc., 30301 Agoura Rd, Suite 210, Agoura Hills, California
91301 (US). **HAMBURGER, Agnes**; c/o A2 Biotherapeu-
tics, Inc., 30301 Agoura Rd, Suite 210, Agoura Hills, Cal-
ifornia 91301 (US). **MOCK, Jee Young**; c/o A2 Biother-
apeutics, Inc., 30301 Agoura Rd, Suite 210, Agoura Hills,
California 91301 (US).(74) Agent: **FARMER, Dean** et al.; Mintz, Levin, Cohn, Fer-
ris, Glovsky and Popeo, P.C., One Financial Center, Boston,
Massachusetts 02111 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: COMPOSITIONS AND METHODS FOR TREATING HER2 POSITIVE CANCERS

FIG. 17



(57) Abstract: The disclosure relates to immune cells comprising a dual receptor system responsive to loss of heterozygosity in a target cell, and methods of making and using same. The first receptor comprises activator receptor specific to a HER2 antigen, and the second receptor comprises an inhibitory receptor specific to an antigen lost in cancer but not wild type cells, that inhibits activation of the immune cells by the first receptor.

[Continued on next page]

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*